

Anti-Bcl-2 Antibody

IRS096RB



Product Type: Recombinant Rabbit monoclonal IgG, primary antibodies

Species reactivity: Human

Applications: mIHC

Molecular Wt: Predicted band size: 26 kDa

Description: Bcl-2, encoded in humans by the BCL2 gene, is the founding member of the Bcl-2 family of regulator proteins. BCL2 blocks programmed cell death (apoptosis) while other BCL2 family members can either inhibit or induce it. It was the first apoptosis regulator identified in any organism. Bcl-2 derives its name from B-cell lymphoma 2, as it is the second member of a range of proteins initially described in chromosomal translocations involving chromosomes 14 and 18 in follicular lymphomas. Orthologs (such as Bcl2 in mice) have been identified in numerous mammals for which complete genome data are available. Like BCL3, BCL5, BCL6, BCL7A, BCL9, and BCL10, it has clinical significance in lymphoma.

Positive control: Human tonsil tissue.

Subcellular location: Mitochondrion outer membrane, Nucleus membrane, Endoplasmic reticulum membrane, Cytoplasm.

Database links: SwissProt: P10415 Human

Recommended Dilutions:

mIHC 1:100

Storage Buffer: PBS, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage Instruction: Shipped at 4°C. Store at +4°C short term (1-2 weeks). It is recommended to aliquot into single-use upon delivery. Store at -20°C long term.

Hangzhou Huaan Biotechnology Co.,Ltd.

Orders:0086-571-88062880

Technical:0086-571-89986345

Service mail:support@huabio.cn

华安生物
HUABIO
www.huabio.cn

Images




Fig1: mIHC analysis of human tonsil tissue (Formalin/PFA-fixed paraffin-embedded sections) with Rabbit anti-Bcl-2 antibody (IRS096RB) at 1/100 dilution. The immunostaining was performed with the IRISKITCmTSA Kit (900808). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 30 mins at 95°C. DAPI (blue) was used as a nuclear counter stain. Image acquisition was performed with Olympus VS200 Slide Scanner.

Note: All products are “FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE”.

Background References

1. Westaby D et al. BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity. *J Clin Invest.* 2024 Sep
2. Liu J et al. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. *Blood.* 2024 May

Hangzhou Huaan Biotechnology Co., Ltd.

Orders:0086-571-88062880

Technical:0086-571-89986345

Service mail:support@huabio.cn

华安生物
HUABIO
www.huabio.cn